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Abstract
X-linked juvenile retinoschisis (XLRS) is a hereditary retinal dystrophy in young males, caused by mutations in the RS1 gene. The function of
the encoded protein, termed retinoschisin, and the molecular mechanisms underlying XLRS pathogenesis are still unresolved, although a direct
interaction partner of the secreted retinoschisin, the retinal Na/K-ATPase, was recently identified. Earlier gene expression studies in retinoschi-
sin-deficient (Rs1h/Y) mice provided a first indication of pathological up-regulation of mitogen-activated protein (MAP) kinase signalling in dis-
ease pathogenesis. To further investigate the role for retinoschisin in MAP kinase regulation, we exposed Y-79 cells and murine Rs1h/Y retinae
to recombinant retinoschisin and the XLRS-associated mutant RS1-C59S. Although normal retinoschisin stably bound to retinal cells, RS1-
C59S exhibited a strongly reduced binding affinity. Simultaneously, exposure to normal retinoschisin significantly reduced phosphorylation of
C-RAF and MAP kinases ERK1/2 in Y-79 cells and murine Rs1h/Y retinae. Expression of MAP kinase target genes C-FOS and EGR1 was also
down-regulated in both model systems. Finally, retinoschisin treatment decreased pro-apoptotic BAX-2 transcript levels in Y-79 cells and
Rs1h/Y retinae. Upon retinoschisin treatment, these cells showed increased resistance against apoptosis, reflected by decreased caspase-3
activity (in Y-79 cells) and increased photoreceptor survival (in Rs1h/Y retinal explants). RS1-C59S did not influence C-RAF or ERK1/2 activa-
tion, C-FOS or EGR1 expression, or apoptosis. Our data imply that retinoschisin is a novel regulator of MAP kinase signalling and exerts an anti-
apoptotic effect on retinal cells. We therefore discuss that disturbances of MAP kinase signalling by retinoschisin deficiency could be an initial
step in XLRS pathogenesis.
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Introduction
Pathogenic alterations affecting the RS1 gene on chromosome
Xp22.1 have been shown to cause XLRS (OMIM #312700) [1], a
macular degeneration disorder in young males with a prevalence of
approximately 1:5000 to 1:20,000 [2]. Disorganization of retinal lay-
ers and distinct abnormalities in the electroretinogram (ERG) are hall-
marks of the disease. Specifically, a characteristic splitting of retinal
layers, presenting as a bilateral foveal schisis, is found at an early
stage of the disease and results in cystic degeneration of the central
retina [3–6]. Additionally, defects in signal transmission from pho-
toreceptor to bipolar cells as visualized by ERG recordings are
observed and reveal a characteristic reduction in the b-wave ampli-
tude, whereas the a-wave remains almost unaffected [4, 7]. Compara-
ble pathological features are also evident in XLRS mice, generated via
a targeted disruption of the murine orthologue of RS1, the Rs1h gene
[8–10]. Due to the close resemblance of the retinal phenotype in
Rs1h knockout mice and XLRS patients, the retinoschisin-deficient
mouse represents an excellent disease model widely used in experi-
mental studies addressing the mechanisms of XLRS pathology but
also novel treatment approaches [11–16].
The RS1 gene is organized into six exons and encodes a 224-
amino acid (aa) precursor protein [1]. It is specifically expressed in
the retina by photoreceptor and bipolar cells, as well as in pinealo-
cytes of the pineal gland [1, 17, 18]. During protein synthesis, a 23-
aa signal sequence is cleaved to produce a 201-aa mature polypeptide
which is secreted from photoreceptors and bipolar cells as a homooc-
tamer held together by intermolecular disulphide bonds between aa
223 and aa 59 [19–22]. So far, over 190 unique XLRS-associated
sequence variants in RS1 have been reported (Leiden Open Variation
Database, http://grenada.lumc.nl/LOVD2/eye/home.php?select_db=
RS1, accessed May 2016). Functional assessment of a subset of
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these variants demonstrated that the vast majority of mutations result
in a complete loss of the functional protein [4].
Despite intensive research, the precise molecular function of reti-
noschisin remains unresolved. Searching for retinoschisin interaction
partners, Molday et al. [14] identified the retina-specific Na/K-ATPase
composed of the two subunits ATP1A3 (a3) and ATP1B2 (b2). Sub-
sequently, our group confirmed the Na/K-ATPase to be required for
anchoring retinoschisin to plasma membranes [23]. The Na/K-ATPase
is a plasma membrane spanning ion pump, responsible for maintain-
ing the cellular membrane potential by transporting Na+ and K+ ions
across the plasma membrane against their electrochemical gradient
[24, 25]. Despite this essential task, Na/K-ATPases also mediate inter-
cellular adhesion [26–28] and induce activation of intracellular sig-
nalling pathways upon binding of glycoside hormones such as
ouabain [25, 29–34]. Members of the FXYD family, a class of Na/K-
ATPase-binding proteins [35, 36], were reported to be important reg-
ulators of the Na/K-ATPase, modulating its pump activity and media-
tion of intercellular adhesion [37–39]. Similar to FXYD proteins, one
could consider retinoschisin to exert a role as a modulator of Na/K-
ATPase activity.
A genomewide expression analysis of the Rs1h-deficient (Rs1h/Y)
murine retina first indicated an increased activation of the ERK path-
way in early XLRS pathogenesis, prior to apoptotic photoreceptor
degeneration [40]. The ERK pathway is one of the four major MAP
kinase pathways [41, 42] known to play a crucial role in fundamental
developmental and physiological processes such as apoptosis, neuro-
protection, neuronal development and adhesion [41, 43–50]. It is
tempting to speculate that misregulation of MAP kinase signalling
caused by retinoschisin deficiency could be an initial step in XLRS
pathogenesis. However, aberrant MAP kinase activation could also be
a secondary event, caused by alterations of the cellular/retinal home-
ostasis in the XLRS disease process.
In this study, we examined whether retinoschisin binding to reti-
nal membranes directly modulates MAP kinase signalling. Our find-
ings in cultured Y-79 cells and in retinal explants of Rs1h/Y mice
demonstrate that the addition of recombinant retinoschisin, but not
recombinant mutant retinoschisin, significantly down-regulates MAP
kinase signalling, as well as protects against apoptosis. We conclude
that retinoschisin deficiency could be a trigger for disease pathogene-
sis by a defective control of MAP kinase signalling and apoptosis in
the retina.
Materials and methods
Animal models
The Rs1h/Y mouse was generated as described earlier [9] and kept on
a C57BL/6 background. Mice were housed under specific pathogen-free
barrier conditions at the Central Animal Facility of the University of
Regensburg and maintained under conditions established by the institu-
tion for their use, in strict compliance with NIH guidelines. Mice were
sacrificed 10 or 18 days after birth by decapitation or cervical disloca-
tion after inhalation of carbon dioxide, respectively.
Cell culture
Y-79 and Weri-Rb1 (ATCC, Manassas, VA, USA) cells were cultivated in
RPMI medium with 10% FCS as well as 100 U/ml penicillin/strepto-
mycin. ARPE-19 cells (ATCC) were maintained in DMEM/Ham’s F12
medium containing 10% FCS and 100 U/ml penicillin/streptomycin. BV-
2 cells were grown in RPMI-1640 with 5% FCS, 100 U/ml penicillin/
streptomycin and 195 nM b-mercaptoethanol. Hek293 cells (Invitrogen,
Carlsbad, CA, USA) were maintained in DMEM high glucose medium
containing 10% FCS, 100 U/ml penicillin/streptomycin and 500 lg/ml
G418. All media and cell culture supplies were purchased from Life
Technologies (Carlsbad, CA, USA). Cell lines were grown in a 37°C incu-
bator with a 5% CO2 environment and subcultured when they reached
90% confluency for Hek293, BV-2 and ARPE-19 or a concentration of
4–5 9 105 cells/ml for Y-79 and Weri-Rb1. Only Y-79 cells passaged
less than 10 times were applied in signalling or apoptosis assays.
RNA analysis
RNA was isolated from cell lines using the Qiagen RNeasy Mini Kit (Qia-
gen, Venlo, the Netherlands). RNA from murine retinae and cultured
retinal explants was isolated using the PureLinkTM RNA Micro Kit (Invit-
rogen), according to the manufacturers’ protocols. One microgram of
total RNA was transcribed into cDNA using RevertAid M-MuLV Reverse
Transcriptase (Fermentas, St Leon-Rot, Germany) and poly(dT) primers
according to the manufacturer’s instructions. Semiquantitative RT-PCR
was performed as described by [23], with primers given in Table S1.
Quantitative real-time RT-PCR was performed and analysed as pub-
lished [51] with primers given in Table S1.
Western blot analysis
Proteins were separated after application of Laemmli buffer [52] on 12.5%
gels or gradient gels 4–20% Mini-PROTEAN TGXTM Precast Protein Gels
(Bio-Rad Laboratories, Hercules, CA, USA; for analysis of retinoschisin
octamers). For Western blotting, proteins were transferred to polyvinyli-
dene difluoride (PVDF) membranes (Immobilon; Millipore, Schwalbach,
Germany) Antibodies were used as follows: Antibodies against Myc tag,
phospho-c-Raf (Ser338), c-Raf and phospho-44/42-MAPK (Erk1/2;
Thr202/Tyr204) were obtained from Cell Signaling Technologies (Danvers,
MA, USA). Antibodies against ACTB and ERK1/2 were from Sigma-Aldrich
(St. Louis, MO, USA). Secondary anti-rabbit or antimouse IgG horseradish
peroxidase (HRP)-linked antibodies were from Calbiochem (Merck Chemi-
cals GmbH, Schwalbach, Germany). Antibody dilutions were applied
according to the manufacturer’s recommendations. RS1 primary antibody
(diluted 1:10,000) was kindly provided by Prof. Robert Molday, University
of British Columbia, Vancouver, Canada. ClarityTM Western ECL Substrate
(Bio-Rad Laboratories) and an Odyssey FC imager (LI-COR, Lincoln, NE,
USA) were used to visualize Western blots. Densitometric evaluation of
Western blots was carried out using ImageJ (imagej.nih.gov).
Immunolabelling of retinal cryosections
Retinal explants were washed in PBS (2.7 mM KCl, 140 mM NaCl,
10 mM phosphate, pH 7.4) once. Subsequently, they were submerged
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in 4% (w/v) paraformaldehyde and incubated for 1 hr at room temper-
ature. Retinae were washed in PBS twice before they were put in 30%
(w/v) sucrose overnight. Single retinae were then embedded in
Richard-Allan ScientificTM Neg-50TM Frozen Section Medium (Thermo
Fisher Scientific, Waltham, MA, USA) and fast frozen in liquid nitrogen.
About 10 lm cryosections were cut. Immunolabelling with anti-
ATP1B2 and antiretinoschisin antibodies was performed as described
by [23]. Cone visualization was performed with Alexa 488-conjugated
peanut agglutinin (1:250, PNA; Invitrogen). Rhodopsin staining was
performed with Rho-1D4 antibody (1:1000), kindly provided by Prof.
Robert Molday, University of British Columbia, Vancouver, Canada. The
sections were counterstained with 40,6-diamidino-2-phenylindol (DAPI,
1:1000; Molecular Probes, Leiden, the Netherlands). Images were
taken with custom-made VisiScope CSU-X1 Confocal System (Visitron
Systems, Puchheim, Germany) equipped with high-resolution sCMOS
camera (PCO AG, Kehlheim, Germany).
Expression cloning
The coding sequence of non-mutant retinoschisin (NM_000330.3) was
amplified from cDNA of retinal tissue using oligonucleotide primers
containing a EcoRI restriction site at the 50 end and a XhoI restriction
site at the 30 end of the RS1 coding sequence (for primer sequences,
see Table S1). The coding sequence of the XLRS-associated RS1
mutant RS1-C59S (NM_000330.3 (RS1):c.175T>A [p.Cys59Ser]
http://grenada.lumc.nl/LOVD2/eye/home.php?select_db=RS1) was gen-
erated by site-directed mutagenesis on the retinoschisin coding
sequence (primer sequences shown in Table S1). For purification, the
two RS1 variants were each tagged with an N-terminal Myc tag, fol-
lowing the leader sequence (after aa 23). This peptide insertion into
the full-length RS1 coding sequence was performed by fusing the N-
terminal part of both RS1 coding sequences from positions 1 to 69
(aa 1–23) to the N-terminal half of the Myc tag sequence (for primers,
see Table S1). The C-terminal part of both RS1 coding sequences (aa
70 to stop codon) was fused to the C-terminal half of the Myc tag
sequence (for primers, see Table S1). C- and N-terminal RS1 frag-
ments were ligated via a BclI restriction site which was introduced into
the Myc tag, and inserted into the pCDNA3.1TM expression vector
(Thermo Fisher Scientific).
Expression and purification of recombinant RS1
variants
Expression constructs were transfected into Hek293 cells using calcium
phosphate transfection as described by [53]. About 7 hrs after transfec-
tion, the culture medium was replaced by Opti-MEM containing
100 U/ml penicillin/streptomycin (Life Technologies) and cells were cul-
tured for additional 48 hrs.
Myc-tagged retinoschisin and RS1-C59S were isolated from cultiva-
tion media by immunoprecipitation using PierceTM Anti-c-Myc Agarose
(Thermo Fisher Scientific) according to the manufacturer’s instructions.
Concentrations of purified proteins were determined using the Bio-Rad
DCTM Protein Assay Kit (Bio-Rad Laboratories).
For use as a treatment control, Hek293 cells were transfected with
empty pCDNA3.1TM expression vector, and cultivation medium of these
cells was subjected to purification procedure exactly like medium from
cells transfected with RS1 variants.
Purity of purified Myc-tagged RS1 proteins and control eluate was veri-
fied via silver staining, Coomassie Blue staining and Western blot analysis
using antibodies against the Myc tag and against retinoschisin (Fig. S1).
Binding of RS1 protein variants to membranes
Retinoschisin binding to adherent cell lines (BV-2, ARPE and Hek293)
as well as to murine retinal membranes (P10) was assessed as
described by [23], but with a prolonged incubation time of 1 hr.
Retinoschisin binding to suspension cell lines Y-79 and Weri-Rb1
was analysed by incubating 4 9 106 cells in 5 ml RS1 containing med-
ium (from supernatant of stably transfected Hek293 cells [23]) for 1 hr,
with subsequent washing steps as described [23].
For comparing binding affinity of retinoschisin and RS1-C59S to Y-79
cells and Rs1h/Y murine retinal membranes, 6 lg of purified retinoschi-
sin or RS1-C59S was added to 5 ml cultivation medium and incubated for
10, 30 and 60 min. Subsequent steps were performed as above.
For localization of bound recombinant RS1 variants on Rs1h/Y murine
retinae, Rs1h/Y murine retinal explants were incubated with 1 lg RS1,
RS1-C59S or control eluate, as described in signalling experiments. After
30 min. of incubation, the retinal tissue was washed with PBS once before
immunolabelling of retinal cryosections was performed.
Analysis of signalling pathways in retinal
explants and Y-79 cells
Y-79 cells were grown to a concentration of 4–5 9 105 cells/ml in
10 ml medium. The experiment was started by adding 1 lg purified
retinoschisin or RS1-C59S, or equal volume of control eluate. After 10
or 30 min. of incubation at 37°C, cells were harvested by centrifugation.
For Western blotting, cells were resuspended in 200 ll of pre-cooled
PBS with PhosSTOPTM phosphatase inhibitor (Sigma-Aldrich) and lysed
by sonication (10 sec., 40% intensity). For RNA isolation, cells were
washed once with pre-cooled PBS before they were subjected to RNA
isolation.
Eyes from Rs1h/Y mice at post-natal day 10 were enucleated and
retinal explants were dissected as described by [54]. Retinae were incu-
bated in 800 ll DMEM/Ham’s F12 containing 10% FCS, 100 U/ml peni-
cillin/streptomycin, 2 mM L-glutamine and 2 lg/ml insulin (Thermo
Fisher Scientific). One microgram purified retinoschisin or RS1-C59S or
equal volumes of control eluate were added. After 10 or 30 min. of
incubation at 37°C, retinal explants were removed from medium and
transferred to 200 ll of pre-cooled PBS containing PhosSTOPTM phos-
phatase inhibitor. For Western blot analysis, retinal explants were soni-
cated for 10 sec. at 40% intensity. For RNA isolation, retinal explants
were immediately transferred into lysis buffer (PureLinkTM RNA Micro
Kit; Invitrogen).
Analysis of caspase-3 activity in Y-79 cells
About 2 9 106 cells/well were seeded onto poly-L-lysine-coated 24-well
plates. Cells were allowed to adhere overnight before 0.1 lg of purified
retinoschisin or RS1-C59S, or equal volumes of control eluate were
added to 1 ml medium per well. After 1 hr, the culture medium was
changed to 1 ml RPMI (containing RS1 variants or control eluate as
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before) and 0.2 mM H2O2 to induce apoptosis or 0 mM H2O2 as con-
trol. After 2 hrs, the medium was replaced by 1 ml RPMI containing
RS1 variants or control eluate as before. Cells were allowed to recover
for 18 hrs before they were subjected to a caspase-3 activity test using
the EnzChek Caspase-3 Assay Kit #2 by Thermo Fisher Scientific
according to the manufacturer’s directions.
Analysis of photoreceptor degeneration in retinal
explants
Eyes were enucleated from mice at post-natal day 18 and retinae were
dissected as described before [55]. Five retinae each were subjected to
treatment with retinoschisin, RS1-C59S and control protein. Retinal
explants were transferred into pre-warmed medium (DMEM/Ham’s F12
containing 10% FCS, 100 U/ml antibiotic–antimytotic, 2 mM L-glutamine
and 2 lg/ml insulin, all from Life Technologies) immediately after
preparation, rinsed once in pre-warmed medium and then transferred
onto Track Etch Membrane Filters (Whatman plc, Maidstone, UK) in 35-
mm tissue culture dishes containing 3 ml of medium to which 1 lg of
purified retinoschisin, RS1-C59S or control eluate had been added. The
retinal explants on the filters were covered in a small droplet of med-
ium. Cultivation was carried out under sterile conditions in a 37°C incu-
bator with a 5% CO2 environment. Medium was replaced every 36 hrs
and total cultivation time was 1 week. Subsequently, the retinal explants
were fixed, cryopreserved and cut into 10-lm sections for subsequent
histological analyses as described before. After PNA staining, cones
were counted in each two different sections of the same retina, in 200-
nm-wide regions to the left and the right side of the optic nerve. Rods
were stained with anti-Rho-1D4 antibody. Staining signals of each two
different sections of the same retina, in 200-nm-wide regions to the left
and the right side of the optic nerve, were quantified using ImageJ.
Results
Increased MAP kinase signalling in murine
Rs1h/Y retinae
A study by Gehrig et al. [40] previously indicated up-regulated MAP
kinase activity in early retinal development of Rs1h/Y mice. The
authors found in the murine Rs1h/Y retinae increased phosphoryla-
tion of extracellular-signal-regulated kinases 1 and 2 (Erk1/2), as well
as up-regulated expression of Egr1 (early growth response protein 1),
a prominent target gene of activated MAP kinases [56].
To first verify these results, we analysed phosphorylation of Erk1/2
as well as Egr1 expression in retinae of wild-type and Rs1h/Y mice, 7,
10 and 14 days after birth (P7, P10 and P14). Furthermore, we investi-
gated phosphorylation of c-Raf, a central constituent of the ERK path-
way, the activation of which precedes and is required for Erk1/2
phosphorylation [57], in P7, P10 and P14 retinae. As an additional MAP
kinase target gene, we assessed expression of the FBJ murine osteosar-
coma viral oncogene homologue gene (c-Fos), which is expressed in
response to transient and sustained ERK signalling [56, 58–61].
Western blot analyses showed an increase in c-Raf and Erk1/2
phosphorylation in Rs1h/Y retinae compared with wild-type retina
(Fig. 1A). C-Raf phosphorylation levels in Rs1h/Y retinae increased
to around 150–200%, whereas Erk1/2 phosphorylation levels rose to
around 250–300% above normal (Fig. 1B). These differences were
obtained in all stages (P7, P10 and P14), and each were statistically
significant (P < 0.05, except for c-Raf at P10; Fig. 1A and B) Reti-
noschisin deficiency had no influence on levels of total c-Raf and
Erk1/2, independent of the post-natal stages.
Expression of MAP kinase target genes C-Fos and Egr1 was
increased in Rs1h/Y retinae, at all developmental stages; c-Fos
expression levels in Rs1h/Y retinae were between 150% and 250%,
and Egr1 expression levels between 175% and 300% compared with
wild-type retinae. Differences in expression were statistically signifi-
cant between wild-type and Rs1h/Y retinae (P < 0.05).
Binding of retinoschisin to different retinal cell
types
Searching for an in vitro model system applicable for analysing the
influence of retinoschisin on MAP kinase signalling, we tested differ-
ent retinal cells including murine microglial cell line BV-2, human
RPE-derived cell line ARPE-19, the human retinoblastoma cell lines Y-
79 and Weri-Rb1 for their capacity to bind retinoschisin (Fig. 2A). In
these cells, we also investigated endogenous expression of the retinal
Na/K-ATPase subunits ATP1A3 and ATP1B2, required for anchoring
retinoschisin to retinal plasma membranes [23] (Fig. 2B and C).
Retinoschisin binding assays were performed on intact cells as
described by [23]. Retinoschisin binding to Hek293 cells and crude
membranes of Rs1h/Y retinae served as negative and positive con-
trols, respectively [23]. Efficient retinoschisin binding was found with
Y-79, Weri-Rb1 and membranes of Rs1h/Y retinae, but not with
ARPE-19, BV-2 and Hek293.
Semiquantitative RT-PCR (Fig. 2B) and Western blot analyses
(Fig. 2C) revealed endogenous expression of ATP1A3 and ATP1B2
only in Y-79 and Weri-Rb1. Weri-Rb1 cells also weakly expressed
retinoschisin (Fig. 2B and C). In all further analyses, Y-79 cells were
used to assess effects of externally added retinoschisin on intracellu-
lar signalling.
Different binding affinities of normal
retinoschisin and the XLRS-associated mutant
protein RS1-C59S to retinal membranes
To analyse functional properties of retinoschisin, we heterolo-
gously expressed RS1 (NM_000330.3) and the XLRS-associated
mutant protein (NM_000330.3(RS1):c.175T>A [p.Cys59Ser], ter-
med RS1-C59S, in Hek293 cells. The mutation c.175T>A
[p.Cys59Ser] is one of the rare XLRS variants which are not sub-
jected to co- or post-translational degradation, but instead are
translated and secreted from cells, although not as a stable octa-
mer but instead as a dimer [21, 22]. For purification, retinoschisin
(normal and mutant) was fused to an N-terminal Myc tag, which
did not influence secretion, oligomerization or binding capacities
of the resulting protein (Fig. 2D and E).
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Y-79 cells and Rs1h/Y retinal explants exposed to recombinant
retinoschisin for 10, 30 and 60 min. stably bound the externally
added retinoschisin, even after only 10 min. of incubation (Fig. 2E).
Notably, RS1-C59S exhibited a strongly reduced binding affinity to Y-
79 cells and Rs1h/Y retinal explants (Fig. 2E).
Immunohistochemical stainings of murine Rs1h/Y retinal
explants after treatment with retinoschisin for 30 min. (Fig. 2F) con-
firmed the binding of externally added recombinant retinoschisin.
Recombinant retinoschisin colocalized with the endogenously
expressed retinal Na/K-ATPase of the murine retina at the inner seg-
ments of photoreceptor cells. This is in agreement with the localiza-
tion of retinoschisin in wild-type retinae [23]. In contrast to the
known retinoschisin localization, no recombinant retinoschisin was
detected in the plexiform layers of the retinal explants, which could
possibly be explained by limited diffusion of the externally added reti-
noschisin through the retinal layers. No retinoschisin staining was
observed in immunohistochemical analyses of Rs1h/Y retinal
explants treated with RS1-C59S or control protein (Fig. 2F).
Extracellular retinoschisin modulates ERK 1/2
signalling in Y-79 cells and Rs1h/Y murine
retinal explants
To assess the capacity of retinoschisin to directly modulate
intracellular ERK1/2 signalling, we investigated an influence of
extracellularly added recombinant retinoschisin (normal and
mutant) on phosphorylation of C-RAF and ERK1/2 in Y-79 cells
(Fig. 3) and Rs1h/Y murine retinal explants (Fig. 4). As control,
we applied protein purified from supernatant of mock vector-
transfected cells.
In Y-79 cells, we observed a down-regulation of phosphorylated
C-RAF (77.6  9.7%) after 10 min. of treatment with recombinant
retinoschisin (Fig. 3A). In contrast, RS1-C59S failed to inhibit C-RAF
phosphorylation (Fig. 3A). The differences in phosphorylated C-RAF
levels between retinoschisin treatment and control or RS1-C59S
treatment were statistically significant (P < 0.05). The effect of reti-
noschisin on C-RAF phosphorylation was still evident after 30 min. of
treatment with retinoschisin, where C-RAF phosphorylation was
reduced to 78.4  17.0% (Fig. 3B).
In contrast to its effect on C-RAF in Y-79 cells, retinoschisin treat-
ment failed to show a significant decrease in ERK1/2 phosphorylation
after 10 min. of incubation (Fig. 3A). Thirty minutes of retinoschisin
treatment (Fig. 3B), however, reduced ERK activation to around
69.6  5.3% in Y-79 cells (P < 0.05 compared with control protein
or RS1-C59S). No alterations in total C-RAF and total ERK1/2 protein
levels were detected, excluding an effect of retinoschisin on expres-
sion or stability of the two proteins (Fig. 3).
MAP kinase signalling in murine Rs1h/Y retinal explants was
similarly affected by retinoschisin treatment (Fig. 4). After
10 min. of incubation with retinoschisin, phosphorylated c-Raf
levels were decreased to 73.4  16.3% (Fig. 4A). RS1-C59S
treatment had no effect on c-Raf phosphorylation. The differences
in phosphorylated c-Raf levels were statistically highly significant
Fig. 1 Influence of retinoschisin deficiency on MAP kinase signalling in the murine retina. C-Raf and Erk1/2 phosphorylation in murine wild-type and
Rs1h/Y retinae, harvested at post-natal days 7, 10 and 14 (P7, P10 and P14). Retinal lysates were subjected to Western blot analyses with antibod-
ies against phosphorylated c-Raf (pRaf), total c-Raf (Raf), phosphorylated Erk1 and Erk2 (pErk1/2), total Erk1 and Erk2 (Erk1/2), as well as ActB as
a control (A). Densitometric quantification (B) was performed with immunoblots from three independent sample sets. Signals for pErk1/2, Erk1/2,
pRaf and Raf were normalized against ActB and calibrated against signals for wild-type retinae. Data represent the mean + S.D. (C) C-Fos and Egr1
expression in murine wild-type and Rs1h/Y retinae harvested at post-natal days 7, 10 and 14 (P7, P10 and P14). mRNA expression of C-Fos and
Egr1 was determined via quantitative real-time RT-PCR. Five independent sample sets were analysed. Results were normalized to Hprt transcript
levels and calibrated with the control. The mean + S.D. for the three (immunoblot analyses) or five (quantitative RT-PCR) independent sample sets
is given. Asterisks mark statistically significant (*P < 0.05) and highly significant (**P < 0.01) differences.
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Fig. 2 Binding of RS1 variants to retinal cells (A) Binding of retinoschisin to cultured retinal cell lines ARPE-19, Y-79, Weri-Rb1 and BV-2: Cells were
incubated for 60 min. with retinoschisin containing supernatant (I, input) of cells stably transfected with a retinoschisin expression vector. Subse-
quently, cells were centrifuged and supernatant (FT, flowthrough) was discarded. After further washing steps (last supernatant, W), cells were pel-
leted (pellet, P). Fractions were subjected to Western blot analyses using an antiretinoschisin antibody. Retinoschisin binding to Hek293 cells and
murine Rs1h/Y retinal membranes served as negative and positive controls, respectively. (B) RT-PCR analysis of ATP1B2, ATP1A3 and RS1 gene
expression in cell lines derived from murine microglia (BV-2), human retinal pigment epithelium (ARPE-19), human retinoblastoma (Y-79 and Weri-
Rb1) and human embryonic kidney (Hek293). GUSB gene expression was assessed as control for RNA integrity. (C) Cell lysates from BV-2, ARPE-
19, Y-79, Weri-Rb1 and Hek293 were subjected to Western blot analyses using antibodies against ATP1B2, ATP1A3 and retinoschisin. Hek293+ cells
served as positive control. The ACTB immunoblot was performed as loading control. (D) Oligomerization of RS1 variants (non-mutant retinoschisin
and RS1-C59S) before and after purification. About 48 hrs after transfection of Hek293 cells with expression constructs for N-terminally Myc-tagged
RS1 variants, the cell culture medium (supernatant) was harvested and Myc-tagged proteins were purified from the supernatant. Aliquots of super-
natant and purified RS1 fractions were subjected to SDS-PAGE under non-reducing and reducing conditions, followed by Western blot analyses
using an antiretinoschisin antibody. (E) Binding of RS1 variants to retinal cells. Y-79 cells and murine Rs1h/Y retinal explants were incubated with
purified RS1 variants (I, input) for 10, 30 and 60 min. Cells were centrifuged and supernatant (FT, flowthrough) was discarded. After several wash-
ing steps (last supernatant, W), cells were pelleted (pellet, P). Fractions were subjected to Western blot analyses using an antiretinoschisin antibody.
(F) Localization of recombinant RS1 variants on retinal membranes. Rs1h/Y retinal explants (P10) were incubated for 30 min. with retinoschisin,
RS1-C59S or control protein, the latter purified from supernatant of empty expression vector-transfected cells. After washing and embedding,
cryosections of these explants were subjected to immunohistochemical analyses using antibodies against ATP1B2 and retinoschisin. 40,6-Diamidino-
2-phenylindol (DAPI) staining shows the nuclei of the different retinal layers. IS, inner segments; ONL, outer nuclear layer; OPL, outer plexiform
layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer.
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(P < 0.01) between control and retinoschisin treatment and sta-
tistically significant (P < 0.05) between retinoschisin and RS1-
C59S treatment. After 30 min. of incubation, the reduction in c-
Raf phosphorylation by retinoschisin treatment was still observ-
able (Fig. 4B): Retinoschisin decreased c-Raf phosphorylation to
81.4  14.1%, compared with the control.
Erk1/2 phosphorylation was not affected after 10 min.
(Fig. 4A), but only after 30 min. of treatment with recombinant
retinoschisin (Fig. 4B). In contrast to control or RS1-C59S treat-
ment, incubation with retinoschisin resulted in a clear reduction
in phosphorylated Erk1/2 (68.7  18.2% compared with control,
Fig. 4B). Differences in phosphorylated Erk1/2 levels were statisti-
cally highly significant (P < 0.01) when compared between con-
trol and retinoschisin treatment and statistically significant
(P < 0.05) between retinoschisin and RS1-C59S treatment. The
different treatments caused no changes in total c-Raf and total
Erk1/2 levels in the retinal explants (Fig. 4).
Extracellular retinoschisin modulates ERK1/2
target gene expression in Y-79 cells and Rs1h/Y
murine retinal explants
Upon treatment with recombinant retinoschisin, a statistically signifi-
cant down-regulation of C-FOS mRNA expression was observed in Y-
79 cells (84.6  7.7%) and in Rs1h/Y murine retinal explants
(68.1  18.9%) by quantitative RT-PCR when compared to control
treatment (P < 0.05, Fig. 5A). In contrast, no prominent decrease in
Fig. 3 Influence of retinoschisin on the ERK pathway in Y-79 cells. Reti-
noschisin-dependent C-RAF and ERK1/2 phosphorylation in Y-79 cells.
Y-79 cells were treated for 10 min. (A) or 30 min. (B) with retinoschi-
sin, RS1-C59S or control protein (purified from supernatant of empty
expression vector-transfected cells). Subsequently, the cells were sub-
jected to Western blot analyses with antibodies against phosphorylated
C-RAF (pRAF), total C-RAF (RAF), phosphorylated ERK1 and ERK2
(pERK1/2), total ERK1 and ERK2 (ERK1/2), as well as ACTB as a con-
trol. (A and B) Densitometric quantification was performed with immu-
noblots from five independent experiments. Signals for pRAF RAF,
pERK1/2 and ERK1/2 were normalized against ACTB and calibrated
against the control. Data represent the mean + S.D. Asterisks mark
statistically significant (*P < 0.05) and highly significant (**P < 0.01)
differences.
Fig. 4 Influence of retinoschisin on the ERK pathway in murine Rs1h/Y
retinal explants. Retinoschisin-dependent c-Raf and Erk1/2 phosphoryla-
tion in murine Rs1h/Y retinal explants. Retinal explants harvested
10 days after birth (P10) were treated for 10 min. (A) or 30 min. (B)
with retinoschisin, RS1-C59S or control protein (purified from super-
natant of empty expression vector-transfected cells). Subsequently, the
retinal lysates were subjected to Western blot analyses with antibodies
against phosphorylated c-Raf (pRaf), total c-Raf (Raf), phosphorylated
Erk1 and Erk2 (pErk1/2), total Erk1 and Erk2 (Erk1/2), as well as ActB
as a control. (A and B) Densitometric quantification was performed with
immunoblots from five independent experiments. Signals for pRaf Raf,
pErk1/2 and Erk1/2 were normalized against ActB and calibrated against
the control. Data represent the mean + S.D. Asterisks mark statistically
significant differences (*P < 0.05).
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C-FOS transcripts was found after treatment with RS1-C59S
(98.4  7.3% for Y-79; 97.7  17.9% for retinal explants). The dif-
ferences between the retinoschisin and the control or RS1-C59S
treatment were statistically significant (P < 0.05; Fig. 5A).
Similarly, retinoschisin treatment caused a statistically significant
decrease in EGR1 expression (Fig. 5B): EGR1 transcript levels were
reduced to 82.0  8.8% in Y-79 cells and to 76.6  18.8% in
Rs1h/Y murine retinal explants (P < 0.05) when compared to con-
trol treatment. No prominent decrease in EGR1 mRNA levels was
found after treatment with RS1-C59S (94.3  7.1% for Y-79 cells,
P < 0.05 compared with retinoschisin treatment, and 92.4  26.2%
for retinal explants).
Retinoschisin is protective for apoptotic events
Mitogen-activated protein kinase signalling is an important mediator
and regulator of several physiological processes implicated in XLRS
pathogenesis [41, 43–50, 62]. As one characteristic feature of Rs1h/
Y mice is an early photoreceptor degeneration due to apoptotic cell
death [63], we analysed the influence of retinoschisin on the expres-
sion of apoptosis marker BAX in Y-79 cells and murine Rs1h/Y reti-
nal explants. Additionally, we assessed retinoschisin-dependent
caspase-3 activation as a prominent marker for apoptosis induction
[64–66] in Y-79 cells, as well as the influence of recombinant reti-
noschisin on cone degeneration in murine Rs1h/Y retinal explants
(Fig. 6).
Short time exposure to retinoschisin caused no change in BAX
transcript levels in Y-79 cells (data not shown). After 20 hrs of incu-
bation, however, BAX transcript levels were significantly decreased
(77.6  14.0%) compared with control (P < 0.05) or RS1-C59S
treatment (P < 0.01, Fig. 6A). In Rs1h/Y retinal explants, 30 min. of
incubation with retinoschisin reduced BAX transcript levels to
85.4  9.3% (P < 0.01 compared with control and RS1-C59S-trea-
ted retinae, Fig. 6A). In contrast, incubation with RS1-C59S had no
significant effect on BAX expression in Y-79 cells (109.5  2.6%) or
retinal explants (103.3  11.8%, Fig. 6A).
Caspases were shown to play a prominent role in photoreceptor
cell death in the retinoschisin-deficient mouse [63]. We thus followed
caspase-3 activation in Y-79 cells upon stress-induced apoptosis
after treatment with 0.2 mM hydrogen peroxide [H2O2] [64–66].
H2O2 treatment caused an about 2.5-fold increase in caspase-3 activ-
ity compared with unstimulated cells (Fig. 6B). Notably, in cells stim-
ulated with H2O2, retinoschisin strongly decreased caspase-3
activation (67.6  9.9%) compared with control protein or RS1-
C59S (P < 0.01). RS1-C59S led to a slight, albeit statistically not sig-
nificant, reduction in caspase-3 activity (87.6  9.1%, P = 0.59) in
H2O2-treated cells.
Finally, we addressed retinoschisin-dependent photoreceptor
survival by following cone and rod degeneration in murine Rs1h/
Y retinal explants [63]. Photoreceptor cell death in Rs1h/Y mice
is triggered by apoptotic events initiated around 14 days after birth
(P14, [63]). We isolated Rs1h/Y retinae 18 days after birth (P18)
and incubated them in medium containing retinoschisin, RS1-C59S
or control protein. One week of cultivation resulted in a strong
degeneration of retinal explants, shown by a markedly decreased
thickness of the central retina and a significant reduction in pho-
toreceptor cells (Fig. 6C–F). More specifically, compared with
untreated retinae, 1 week of cultivation reduced the number of
cones to around 25% in control and RS1-C59S-treated explants
(25.6  8.5% for control and 24.8  8.9% for RS1-C59S treat-
ment (Fig. 6C and D). Notably, in explants treated with
Fig. 5 Influence of retinoschisin on the expression of ERK1/2 pathway target genes. Retinoschisin-dependent C-FOS (A) and EGR1 (B) expression in
Y-79 cells and murine Rs1h/Y retinal explants. Cells/retinal explants were treated as described in Figures 3 and 4 for 2 hrs (Y-79 cells) and
30 min. (murine retinal explants). C-FOS and EGR1 mRNA expression was determined via quantitative real-time RT-PCR. Five independent experi-
ments were performed. Results were normalized to HPRT transcript levels and calibrated with the control. The mean + S.D. for the five independent
experiments is given. Asterisks mark statistically significant differences (*P < 0.05).
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Fig. 6 Influence of retinoschisin on apoptosis. (A) Retinoschisin-dependent BAX expression in Y-79 cells and murine Rs1h/Y retinal explants. Y-79
cells or retinal explants were treated with retinoschisin, RS1-C59S or control protein for 20 hrs or 30 min., respectively. BAX mRNA expression was
determined via quantitative real-time RT-PCR. Five independent experiments were performed. Results were normalized to HPRT transcript levels and
calibrated with the control. The mean + S.D. for the five independent experiments is given. Asterisks mark statistically significant (*P < 0.05) and
highly significant (**P < 0.01) differences. (B) Retinoschisin-dependent activation of caspase-3 in Y-79 cells subjected to oxidative stress. Y-79
cells, exposed to retinoschisin, RS1-C59S or control protein were treated with 0.2 mM H2O2 for 2 hrs. About 18 hrs later, apoptosis was assayed
by following caspase-3-specific proteolytic activity. Data represent the mean + S.D. of six independent experiments. Asterisks mark statistically
highly significant differences (**P < 0.01). (C–F) Retinoschisin-dependent photoreceptor degeneration in murine Rs1h/Y retinal explants. Retinal
explants harvested 18 days after birth (P18) were cultured for 1 week in medium containing retinoschisin, RS1-C59S or control protein (purified
from supernatant of empty expression vector-transfected cells). After washing and embedding, cryosections of these explants were subjected to
staining for nuclei, cones and rods. OS, outer segments; IS, inner segments; ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear
layer; IPL, inner plexiform layer; GCL, ganglion cell layer. DAPI staining shows the nuclei of the different retinal layers. (C) Alexa488-conjugated pea-
nut agglutinin (PNA) staining was applied to visualize cones. (D) The total number of cones per analyzed section was counted after staining with
PNA. (E) Anti-Rho-1D4 antibody staining was applied to visualize rod specific Rhodopsin. (F) Rhodopsin signals per analyzed section were mea-
sured using ImageJ (imagej.nih.gov). Data represent the mean + SD. Asterisks mark statistically highly significant differences (**P < 0.01).
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retinoschisin, the cone number was decreased to only about 50%
(50.3  7.3% compared with untreated retinae), with a statistically
highly significant difference to control and RS1-C59S-treated
explants (P < 0.01). Investigations on rod degeneration revealed
similar results (Fig. 6E and F). After 1 week of cultivation, rod sig-
nals were reduced to around 24.8  9.3% for control treated and
to 28.9  4.7% for RS1-C59S-treated explants. Treatment with
retinoschisin lead to a rod signal decrease of only 59.3  7.6%
compared with untreated retinae, with statistically highly significant
differences to control and RS1-C59S-treated explants (P < 0.01).
Discussion
In this study, we investigated the role of retinoschisin in the regu-
lation of intracellular MAP kinase signalling. Firstly, our experi-
ments confirmed strongly increased MAP kinase signalling in early
retinal development of Rs1h/Y mice. Secondly, we demonstrated
that retinoschisin binding directly decreased phosphorylation of C-
RAF and MAP kinases ERK1 and ERK2, as well as expression of
the MAP kinase target genes C-FOS and EGR1 in a retinal (Y-79)
cell line and in murine Rs1h/Y retinal explants. Thirdly, our data
suggest a protective effect of retinoschisin against apoptotic cell
death in Y-79 cells and Rs1h/Y retinal explants. As a stringent
control, the XLRS mutant RS1-C59S was deficient in binding to
retinal membranes, and failed to reveal regulation on MAP kinase
signalling or effects on apoptosis. Together, our results demon-
strate that retinoschisin is a novel regulator of intracellular sig-
nalling and protects retinal cells from apoptosis. We suggest that
aberrant MAP kinase signalling due to retinoschisin deficiency
could be an initial trigger in XLRS pathogenesis.
In recent years, the importance of MAP kinase signalling in retinal
development and homeostasis has attracted increasing attention [67–
69]. Not surprisingly, several retinal dystrophies such as age-related
macular degeneration [70–72], diabetic retinopathy [73] or retinitis pig-
mentosa [74, 75] were linked to malfunctioning MAP kinase pathways.
Aberrant MAP kinase signalling was also observed during early retinal
development in the XLRS mouse model [40]. Our study verified the ear-
lier observations from Gehrig et al. [40] by showing increased activation
of central constituents of the ERK pathway, c-Raf and Erk1/2 [57], in
Rs1h/Y retinae of 7-, 10- and 14-day-old mice. Furthermore, we showed
up-regulation of prominent target genes of MAP kinase signalling,
namely c-Fos and Egr1 [56], indicating an early and sustained alteration
in MAP kinase signalling in disease development of Rs1h/Y mice.
To assess whether retinoschisin has the capacity to directly mod-
ulate MAP kinase signalling, we investigated the effect of recombinant
retinoschisin on activation of the ERK pathway in two retinal model
systems; the human retinoblastoma cell line Y-79 and Rs1h/Y mur-
ine retinal explants, both capable to bind extracellularly added reti-
noschisin due to an endogenous expression of the NA/K-ATPase
subunits a3 and b2. The addition of recombinant retinoschisin had an
immediate and significant influence on MAP kinase signalling in these
two model systems, reflected by decreased C-RAF and ERK1/2 phos-
phorylation. C-RAF activation (10 min.) occurred before ERK1/2
phosphorylation (30 min. after addition of retinoschisin), in
agreement with the established sequence of C-RAF and ERK1/2 acti-
vation in the ERK signalling cascade [57, 76]. Subsequently, reti-
noschisin treatment also induced down-regulation of C-FOS and
EGR1 expression in Y79 cells and Rs1h/Y murine retinal explants.
These results establish retinoschisin as an important regulator of the
MAP kinase pathway in retinal cells.
The contribution of MAP kinase signalling to various disease
processes can be explained by its key role in the regulation of
complex physiological processes such as apoptosis, adhesion, pro-
liferation, differentiation or development [41, 44, 49]. For instance,
several studies showed a pro-apoptotic effect of ERK activation
specifically connected to neuronal cells, for example in neurode-
generative disease processes [77–80]. Of note, a characteristic
increase in ERK1/2 activation with an effect size similar to our
results has been described for early disease stages of Alzheimer’s
disease with 25% less ERK1/2 activation in temporal cortex of
healthy individuals compared with patients [81], or of ocular
ischaemic syndrome where 29% less ERK1 and 21% less ERK2
activation in murine retinae of control mice were found when com-
pared to a mouse model of ocular ischaemic syndrome [82]. Addi-
tionally, comparably small alterations in MAP kinase signalling,
related to cellular survival, were found in natural killer cells of
chronic fatigue syndrome [83] and in lymphocytes of patients with
Alzheimer’s and Parkinson’s disease [84].
Consistently, we demonstrate a protective influence of retinoschisin
against apoptosis: Transcript levels of the pro-apoptotic BAX protein [85,
86] were down-regulated in Y-79 cells and Rs1h/Y retinae exposed to
recombinant retinoschisin. Furthermore, in Y-79 cells subjected to oxida-
tive stress, caspase-3 activity, a marker for the induction of apoptosis
[65], was significantly decreased by retinoschisin. Similarly, apoptosis-
induced cone and rod degeneration [63] in murine Rs1h/Y retinal
explants was strongly reduced in the presence of recombinant reti-
noschisin. Further studies are required to verify the direct contribution of
increased MAP kinase activation to photoreceptor apoptosis in XLRS
pathogenesis. Nevertheless, considering the current state of knowledge
on the pathological role of MAP kinase activation in neurodegeneration
[77–82], we speculate that increased MAP kinase signalling due to reti-
noschisin deficiency can induce or contribute to XLRS-associated neu-
rodegenerative processes in humans, and apoptotic photoreceptor
degeneration in the XLRS mouse model [40].
Our investigations included studies on the functionality of the
XLRS-associated retinoschisin mutant, RS1-C59S. Unlike most RS1
mutants, RS1-C59S is translated and secreted from cells, but with
defective oligomerization [21, 22]. The functional consequences of
this structural alteration have not been elucidated, so far. Here, we
show that RS1-C59S cannot bind to retinal membranes and can thus
not fulfil its function as a regulator of intracellular signalling.
The present data do not allow elucidation of how extracellular reti-
noschisin binding affects intracellular MAP kinase signalling. Previous
analysis identified the retinal Na/K-ATPase as the specific binding
partner for retinoschisin on retinal membranes [14, 23]. Several
groups reported that in addition to their function as an ion pump [87,
88], Na/K-ATPases are important regulators of intracellular MAP
kinase signalling [31, 89–91], although the exact mechanism of signal
transduction from Na/K-ATPases to the MAP cascade is under debate
10 ª 2016 The Authors.
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[30, 92–96]. It would thus be conceivable that retinoschisin modu-
lates the capacity of the Na/K-ATPase to regulate intracellular sig-
nalling. A disruption of this retinoschisin-Na/K-ATPase signalosome
complex by retinoschisin deficiency could therefore result in defective
MAP kinase regulation by the Na/K-ATPase.
Taken together, we provide evidence that retinoschisin is a
novel regulator of MAP kinase signalling in the retina with the
capacity to protect cells against apoptotic cell death. We suggest
that disturbances of intracellular MAP kinase signalling by reti-
noschisin deficiency might be one of the initial steps in XLRS
pathology. Thus, our data could provide a novel basis for consid-
erations to therapeutic treatments for this progressive and cur-
rently untreatable disease.
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